Taiwanese Upstart Emerges As Threat To Biovail's Wellbutrin XL Patent
Earlier this week, Biovail said Anchen had submitted an abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA) for the drug, known generically as bupropion.
Two other generics manufacturers, Eon and Impax, have indicated they intend to file similar ANDAs in the near future.
Closely held Anchen was formed two years ago by...
To view the full article, register now.